RAD51C Gene Mutation
6
2
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome